Ampio Pharmaceuticals (NYSE:AMPE) vs. Zomedica (OTCMKTS:ZOMDF) Head-To-Head Review

Volatility and Risk

Ampio Pharmaceuticals has a beta of 5.96, meaning that its stock price is 496% more volatile than the S&P 500. Comparatively, Zomedica has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 9.0% of Zomedica shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of Zomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Ampio Pharmaceuticals and Zomedica”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
Zomedica	$32.03 million	3.52	-$81.86 million	($0.09)	-1.28

Ampio Pharmaceuticals has higher earnings, but lower revenue than Zomedica. Zomedica is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ampio Pharmaceuticals and Zomedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Zomedica	-65.92%	-18.83%	-17.21%

Summary

Ampio Pharmaceuticals beats Zomedica on 6 of the 10 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.